Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Isla Health found in HSH's search of the last 24 months.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Isla Health found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
No product recalls, safety notices or clinical safety actions involving Isla Health found in HSH's search of the last 24 months.
Contract delivery, go-lives, terminations and disputes.
Aug 2025: NHS England awarded Isla Health a direct contract worth about £98,000 (ex VAT), running Sep 2025 to Aug 2026, for routine PSA surveillance of men at higher risk of prostate cancer. In Feb 2025 it partnered with the Rotunda Hospital, Dublin.